APRIL Ligand Mutations for BCMA Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma are largely ineffective, and existing therapeutic and diagnostic agents targeting BCMA are hindered by cross-reactivity with TACI, leading to unintended depletion of non-cancerous B and T cells.
Innovation Solution
Development of variant APRIL molecules with altered binding specificity to BCMA, featuring mutations such as M200G, which exhibit a higher BCMA:TACI binding ratio, allowing for more focused targeting of BCMA-expressing cells in therapeutic and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type APRIL is used as a therapeutic agent targeting BCMA, then BCMA-expressing plasma cells can be targeted, but cross-reactivity with TACI causes depletion of non-cancerous B and T cells
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations (M200G, M200C, M200L, M200S, M200A, or M200N) at the M200 position of the APRIL protein. These mutations alter the binding parameters of APRIL to change its affinity and specificity, thereby increasing BCMA binding while reducing TACI binding, which resolves the cross-reactivity issue.
2Measurement precision
If wild-type APRIL is used for diagnostic applications to identify plasma cells, then BCMA-expressing cells can be detected, but ambiguous results occur due to binding with activated T-cells and B-cells
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations (M200G, M200C, M200L, M200S, M200A, or M200N) at the M200 position of the APRIL protein. These mutations alter the binding parameters of APRIL to change its affinity and specificity, thereby increasing BCMA binding while reducing TACI binding, which resolves the cross-reactivity issue.
3Productivity
If standard chemotherapy agents are used for multiple myeloma treatment, then some cancer cells can be killed, but long-term remission is not achieved
Solution Approach 1:
The patent extracts the BCMA-targeting function from non-specific chemotherapy and focuses therapeutic action specifically on BCMA-expressing plasma cells. By using mutated APRIL that selectively binds BCMA with high affinity and low cross-reactivity, the treatment achieves both high efficacy in killing cancer cells and sustained long-term remission by precisely targeting only the malignant population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The variant APRIL molecules demonstrate enhanced specificity and efficacy in targeting BCMA-expressing cells, leading to improved therapeutic outcomes and diagnostic accuracy while minimizing impact on non-cancerous cell populations.
Implementation Method 1
which has a higher binding affinity to BCMA than wild-type APRIL; and/or a higher BCMA:TACI binding ratio than wild-type APRIL
Data Source
Figure 1~2
Figure 3~4
Figure 5A~5C
AI summary
The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.